Skip to main content

Table 3 Univariate and multivariate analyses of PFS and OS in the propensity score-matched cohort

From: A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study

Characteristics

 

PFS

OS

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

HR (95%CI)

P-value

HR (95%CI)

P-value

HR (95%CI)

P-value

HR (95%CI)

P-value

Age (years)

Continuous variable

0.98 (0.95 − 1.01)

0.1148

  

0.98 (0.94 − 1.01)

0.1984

  

Sex

Female/male

0.94 (0.58 − 1.54)

0.8097

  

0.73 (0.42 − 1.26)

0.2574

  

ECOG PS

1 − 3/0

1.44 (0.89 − 2.33)

0.1391

  

1.46 (0.85 − 2.51)

0.1747

  

Smoking history

Never-smoker/smoker

1.00 (0.61 − 1.63)

0.9876

  

0.74 (0.43 − 1.30)

0.2985

  

Immune checkpoint inhibitor

Nivolumab/pembrolizumab

2.10 (1.33 − 3.34)

0.0016

2.07 (1.30 − 3.28)

0.0021

2.31 (1.38 − 3.87)

0.0015

  

Line of treatment

Second or higher/first

1.68 (1.01 − 2.78)

0.0440

  

1.74 (0.97 − 3.12)

0.0613

  

Histology

Sq/non-Sq

1.62 (0.98 − 2.67)

0.0590

1.55 (0.94 − 2.57)

0.0849

1.57 (0.92 − 2.67)

0.0954

1.80 (1.05 − 3.09)

0.0337

Clinical stage

Advanced/recurrent

1.25 (0.72 − 2.16)

0.4332

  

0.90 (0.48 − 1.68)

0.7433

  

Body mass index (kg/m2)

< 22/≥22

0.90 (0.58 − 1.42)

0.6637

  

0.84 (0.51 − 1.38)

0.4834

  

Mutation status (EGFR or ALK)

Othersa /wild-type

1.02 (0.54 − 1.93)

0.9529

  

0.85 (0.41 − 1.73)

0.6498

  

PD-L1 tumor proportion score

Othersb/≥50%

1.90 (1.17 − 3.10)

0.0100

  

2.36 (1.33 − 4.18)

0.0033

2.29 (1.28 − 4.08)

0.0052

Statin therapy

Yes/no

0.76 (0.48 − 1.19)

0.2277

  

0.60 (0.36 − 0.99)

0.0456

0.61 (0.36 − 1.02)

0.0585

  1. ALK anaplastic lymphoma kinase, CI confidence interval, ECOG Eastern Cooperative Oncology Group, EGFR epidermal growth factor receptor, HR hazard ratio, OS overall survival, PD-L1 programmed cell death-ligand 1, PFS progression-free survival, PS performance status, Sq squamous cell carcinoma
  2. aMutation plus unknown
  3. b < 50% or unknown